Q-omics provides the consensus-scored GATD3B profile across patient tissues and cancer cell-line models. GATD3B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GATD3B is differentially expressed in 4, with the highest sampling consensus in KICH. Additionally, GATD3B RNA expression shows 13,518 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KICH, and ACC as cancer lineages where GATD3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GATD3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GATD3B survival associations across molecular data types. GATD3B RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GATD3B RNA expression–survival associations across cancer types. High GATD3B expression shows unfavorable associations in UVM, CESC, LGG and COAD, but favorable associations in STAD and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GATD3B RNA expression.
This table summarizes GATD3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for GATD3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GATD3B shows lower tumor expression in KICH, KIRP and KIRC and higher tumor expression in PRAD. The KICH box plot shows higher GATD3B RNA expression in normal versus tumor tissue (log2 FC = −0.601, t-test p = .012).
This table shows molecular features associated with GATD3B in patient tissues and cancer cell lines. In patient samples, GATD3B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GATD3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
